Viatris Inc. hits a 52-week high, driven by a strong late-stage pipeline, but shares corrected on Effexor sales decline.

When looking to treat erectile dysfunction, there are two commonly used treatment options available for patients. These are Viagra and sildenafil: two similar but distinct types of medication. Both ...

A brewing showdown over legal fees has the makings of a steel cage grudge match, securities law-style. In one corner is Ted Frank, co-founder of the non-profit Hamilton Lincoln Law Institute, who has ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

PFE trades at just 8x forward earnings while paying a near-7% dividend yield, and the five-year base case model targets $49. Pfizer's Berobenatide GLP-1 posted 16% weight loss at 32 weeks with no ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer—the maker of Paxlovid—has begun Phase 3 clinical ...

Precedential and Key Federal Circuit Opinions - 1. ENANTA PHARMACEUTICALS, INC v. PFIZER INC. (2025-1427, 6/23/2026) (Lourie, ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I taking METFORMIN XR MYLAN? METFORMIN XR MYLAN contains the ...

As a participant in the MDRP, Lilly is required to pay a rebate for all drugs dispensed to Medicaid beneficiaries. The required rebate is set by statute and is intended to ensure the net price of a ...

June 15 - Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and research in the country. Pharmaceutical companies including Eli Lilly ...

The Trump administration’s dramatic reworking of U.S. public-health agencies’ approach to vaccines is creating a difficult and unpredictable situation for drugmakers.